CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 24 enrolled
Drug / intervention
Arm A: Everolimus +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01936519
NCT01936519N/ACompleted
CompareCT.gov

A Randomized Prospective Trial of Conversion to Everolimus Therapy From Calcineurin Inhibitor Based Maintenance Immunosuppression in Association With Mycophenolic Acid in Liver Transplantation: Examination of Impact on Long Term Renal Function.

Milton S. Hershey Medical Center·interventional·Posted Sep 6, 2013·Updated Jan 29, 2021

In Brief

A clinical study evaluating Arm A: Everolimus and Calcineurin Inhibitor for Immunosuppression and Renal Failure. Completed, enrolled 24 participants across 1 site.

Detailed Summary

This study will examine the renal sparing impact of implementing a strategy of conversion to everolimus from a calcineurin inhibitor based immunosuppressive protocol at 3 months post liver transplant

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmunosuppression, Renal Failure
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 6, 2013
Enrollment StartDec 16, 2013
Primary CompletionJul 31, 2019
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 12.8 years ago

Interventions

Arm A: Everolimusdrug

Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.

Calcineurin Inhibitordrug

Comparison Arm: Continuation with standard immunosuppressive therapy consisting of Calcineurin inhibitor associated with mycophenolic acid (Myfortic: MPA).